ROVI Rebrands as ROIS, Expands U.S. Operations with $100M Phoenix Manufacturing Facility Acquisition
核心洞察
ROVI (搜索)'s CDMO business unit has rebranded as ROIS (搜索) and acquired a sterile injectable manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb (搜索), marking its entry into direct U.S. production.
The 34,000 square meter facility has received over $100 million in capital investment since 2021 and holds regulatory approvals from FDA, EMA, and Japan's PMDA.
ROIS (搜索) plans to install an Optima pre-filled syringe isolator line by 2027, which will add 65-70 million units of annual PFS capacity to support global pharmaceutical and biotech clients.
ROVI (搜索)'s Contract Development and Manufacturing Organization (CDMO) business unit has completed a strategic transformation, rebranding as ROIS (搜索) while simultaneously acquiring a major sterile injectable drug product manufacturing facility in Phoenix, Arizona from Bristol Myers Squibb (搜索). This dual initiative marks a pivotal expansion of the company's global manufacturing footprint and establishes direct U.S. production capabilities for the first time.
Strategic Facility Acquisition
The Phoenix site represents a substantial addition to ROIS (搜索)'s manufacturing network, spanning approximately 34,000 square meters on an 80,000 square meter campus. The facility has been the recipient of significant capital investment, receiving over $100 million in funding since 2021 to enhance its capabilities and infrastructure.
The manufacturing site includes specialized cytotoxic and high-potent (OEB5) production areas, positioning ROIS (搜索) to handle complex injectable formulations requiring enhanced containment protocols. The facility maintains comprehensive regulatory approvals from key global authorities, including the U.S. Food and Drug Administration (搜索), European Medicines Agency (搜索), and Japan's Pharmaceuticals and Medical Devices Agency (搜索).
Capacity Expansion Plans
ROIS (搜索) has outlined ambitious expansion plans for the Phoenix facility, with a key focus on pre-filled syringe manufacturing capabilities. The company intends to install an Optima pre-filled syringe (PFS) isolator line by 2027, which is projected to add 65-70 million units of annual PFS capacity to the company's global production capabilities.
"This acquisition is a strategic step in building ROIS (搜索) as a global CDMO for high-value injectables," said Javier López-Belmonte, Vice Chairman of the Board and Chief Financial Officer. "The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on U.S. soil while continuing to invest across our network."
Global CDMO Positioning
The rebranding to ROIS (搜索) reflects the company's evolution from a European-focused operation to a transatlantic CDMO with enhanced service capabilities. The company has established a strong reputation in Europe for injectable development and manufacturing, and the new identity signals its strategic intent to become a global partner of choice for pharmaceutical and biotech clients.
The Phoenix acquisition provides ROIS (搜索) with direct U.S.-based manufacturing capabilities, enabling the company to better serve North American clients while maintaining its established European operations. This geographic diversification is expected to increase global capacity and operational flexibility for the organization.
Leadership Vision
López-Belmonte emphasized the transformative nature of the company's strategic direction, stating, "Our transformation into ROIS (搜索) reflects where we are today and where we are headed. We are proud of our legacy and excited about our future — growing, investing, and expanding capacity to meet our partners' needs worldwide."
The acquisition and rebranding initiative represents ROIS (搜索)'s commitment to ongoing investment in technology, infrastructure, and service offerings as it positions itself for continued growth in the competitive CDMO market. The company's focus on high-value injectables, combined with its expanded geographic presence, is designed to strengthen its market position and enhance its ability to serve global pharmaceutical and biotechnology partners.